Movement Alert｜Corcept Therapeutics Overnight Rise 20.02%, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance

Market Focus07-30

On July 30, Corcept Therapeutics surged 20.02% overnight, trading at $111.56/share, with Turnover of $1,159.29.

The rally was driven by the company's Q2 earnings release, which far exceeded market expectations. Corcept reported EPS of $0.36, dramatically beating the consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, surpassing analyst expectations of approximately $221 million by roughly 16%.

Additionally, the company raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong performance was attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. The company also resubmitted its New Drug Application for Relacorilant to treat Cushing's syndrome in June, while Canaccord Genuity raised its price target from $135 to $150.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118244094?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 08:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118244094","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Corcept Therapeutics Overnight Rise 20.02%, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance","media":"Market Focus","content":"<p><p>On July 30, Corcept Therapeutics surged 20.02% overnight, trading at $111.56/share, with Turnover of $1,159.29.</p><p>The rally was driven by the company's Q2 earnings release, which far exceeded market expectations. Corcept reported EPS of $0.36, dramatically beating the consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, surpassing analyst expectations of approximately $221 million by roughly 16%.</p><p>Additionally, the company raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong performance was attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. The company also resubmitted its New Drug Application for Relacorilant to treat Cushing's syndrome in June, while Canaccord Genuity raised its price target from $135 to $150.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Corcept Therapeutics Overnight Rise 20.02%, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Corcept Therapeutics Overnight Rise 20.02%, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 08:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, Corcept Therapeutics surged 20.02% overnight, trading at $111.56/share, with Turnover of $1,159.29.</p><p>The rally was driven by the company's Q2 earnings release, which far exceeded market expectations. Corcept reported EPS of $0.36, dramatically beating the consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, surpassing analyst expectations of approximately $221 million by roughly 16%.</p><p>Additionally, the company raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong performance was attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. The company also resubmitted its New Drug Application for Relacorilant to treat Cushing's syndrome in June, while Canaccord Genuity raised its price target from $135 to $150.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1118244094","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118244094","pubTimestamp":1785370863,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Corcept Therapeutics surged 20.02% overnight, trading at $111.56/share, with Turnover of $1,159.29.The rally was driven by the company's Q2 earnings release, which far exceeded market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"走势警报|Corcept Therapeutics 隔夜上涨 20.02%，第二季度盈利大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"On July 30, Corcept Therapeutics surged 20.02% overnight, trading at $111.56/share, with Turnover of $1,159.29.The rally was driven by the company's Q2 earnings release, which far exceeded market expectations. Corcept reported EPS of $0.36, dramatically beating the consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, surpassing analyst expectations of approximately $221 million by roughly 16%.Additionally, the company raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong performance was attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. The company also resubmitted its New Drug Application for Relacorilant to treat Cushing's syndrome in June, while Canaccord Genuity raised its price target from $135 to $150.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118244094","isCrawlerRequest":true}